Cat. No.: HY-B0338

Rimantadine

Name: Rimantadine
Brand: MedChemExpress
SKU: HY-B0338
Price: 50.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: 1-Rimantadine)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Rimantadine (1-Rimantadine) is an orally active inhibitor for M2 protein, which blocks the hydrogen ion channel activity, prevents the entry and replication of the virus, and exhibits board-spectrum antiviral activity. Rimantadine significantly inhibits hepatitis A virus (HAV) replication at the post-entry stage in Huh7 cells. Rimantadine enhances autophagy. Rimantadine has a significant protective effect against H3N2 virus in mouse model.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.86%
CAS No.: 13392-28-4
Formule: C₁₂H₂₁N
Masse moléculaire:179.30

Stockage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Rimantadine Chemical Structure

CAS No.: 13392-28-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	288 μM Compound: rimantadine	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	4.4 μM Compound: rimantadine	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	7.3 μM Compound: rimantadine	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
Hepatocyte	IC₅₀	35.6 nM Compound: Rimantadine	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
MDCK	CC₅₀	>100 μM Compound: 2	Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method	[PMID: 29541360]
MDCK	CC₅₀	>100 μM Compound: rimantadin	Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay	[PMID: 18778942]
MDCK	CC₅₀	>100 μM Compound: rimantadine	Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 24900429]
MDCK	CC₅₀	>100 μM Compound: Rimantadine	Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
MDCK	CC₅₀	>100 μM Compound: RMN	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 19281225]
MDCK	CC₅₀	>200 μg/mL Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as cell viability by MTS assay Cytotoxicity against MDCK cells assessed as cell viability by MTS assay	[PMID: 20971531]
MDCK	CC₅₀	>200 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	CC₅₀	>200 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	CC₅₀	>200 μM Compound: Rimantadine	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method	[PMID: 31586832]
MDCK	CC₅₀	>400 μM Compound: Rimantadine	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	[PMID: 28477572]
MDCK	CC₅₀	>500 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	CC₅₀	>500 μM Compound: Rimantadine	Cytotoxicity against MDCK cells after 72 hrs by MTS assay Cytotoxicity against MDCK cells after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	CC₅₀	>500 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 28418242]
MDCK	CC₅₀	>500 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay	[PMID: 29886325]
MDCK	CC₅₀	>500 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay	[PMID: 30170320]
MDCK	CC₅₀	1395 μM Compound: Rimantadine	Cytotoxicity against dog MDCK cells after 48 hrs by MTT assay Cytotoxicity against dog MDCK cells after 48 hrs by MTT assay	[PMID: 23489622]
MDCK	CC₅₀	203 μM Compound: Rimantadine	Cytotoxicity against MDCK cells after 72 hrs by MTS assay Cytotoxicity against MDCK cells after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	CC₅₀	218 μM Compound: Rimantadine	Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay	[PMID: 23117173]
MDCK	CC₅₀	318.9 μM Compound: Rimantadine	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 29716780]
MDCK	CC₅₀	326 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay	[PMID: 33171219]
MDCK	CC₅₀	335 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30746065]
MDCK	CC₅₀	335.2 μM Compound: Rimantadine	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 30108810]
MDCK	CC₅₀	350 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27591012]
MDCK	CC₅₀	360 μM Compound: Rimantadine	Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay	[PMID: 28886889]
MDCK	CC₅₀	363 μM Compound: Rimantadine	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 28501512]
MDCK	CC₅₀	363 μM Compound: Rimantadine	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay	[PMID: 33129992]
MDCK	CC₅₀	472 μg/mL Compound: Rimantadin	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 20724039]
MDCK	CC₅₀	62 μg/mL Compound: Rimantadine	Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31375291]
MDCK	CC₅₀	62 μM Compound: Rimantadine	Cytotoxicity against MDCK cells after 24 hrs by MTT assay Cytotoxicity against MDCK cells after 24 hrs by MTT assay	[PMID: 30390440]
MDCK	EC₅₀	>100 μM Compound: rimantadine	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	[PMID: 24900429]
MDCK	EC₅₀	>100 μM Compound: rimantadine	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	>100 μM Compound: Rimantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	>100 μM Compound: RMN	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	>100 μM Compound: RMN	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	>100 μM Compound: RMN	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	>100 μM Compound: RMN	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	>200 μg/mL Compound: Rimantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	>200 μg/mL Compound: Rimantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	>200 μM Compound: Rimantadine	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	>200 μM Compound: Rimantadine	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	>200 μM Compound: Rimantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	>200 μM Compound: Rimantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	>200 μM Compound: rimantadine	Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis	[PMID: 24237039]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	>500 μM Compound: Rimantadine	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	≤ 0.362 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay	[PMID: 20805012]
MDCK	EC₅₀	0.01 μM Compound: rimantadine	Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	0.02 μg/mL Compound: Rimantadine	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	0.02 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as virus plaque reduction preincubated for 1 hr followed by compound wash out and incubated for 72 hrs by crystal violet staining Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as virus plaque reduction preincubated for 1 hr followed by compound wash out and incubated for 72 hrs by crystal violet staining	[PMID: 25899336]
MDCK	EC₅₀	0.03 μg/mL Compound: Rimantadine	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	0.046 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	0.051 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	0.08 μM Compound: Rimantadine	Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	0.12 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	EC₅₀	0.15 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25899336]
MDCK	EC₅₀	0.17 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	0.362 μM Compound: rimantadine	Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay	[PMID: 17588747]
MDCK	EC₅₀	0.45 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	0.5 μM Compound: rimantadine	Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	0.53 μM Compound: 2	Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	0.62 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis	[PMID: 24237039]
MDCK	EC₅₀	0.81 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25899336]
MDCK	EC₅₀	0.85 μM Compound: rimantadine	Antiviral activity against influenza virus A/Hong Kong/7/87 H3N2 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza virus A/Hong Kong/7/87 H3N2 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay	[PMID: 18954995]
MDCK	EC₅₀	1.1 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	1.6 μM Compound: 2	Antiviral activity against Influenza A virus A2/Taiwan/1/64(H2N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus A2/Taiwan/1/64(H2N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	1.9 μM Compound: rimantadine	Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	110 μM Compound: 2	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	12 μg/mL Compound: Rimantadine	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	15 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	17.8 μM Compound: Rimantadine	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	18 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis	[PMID: 24237039]
MDCK	EC₅₀	2.5 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	2.7 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	20 μM Compound: Rimantadine	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	24.2 μM Compound: Rimantadine	Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	29 μM Compound: rimantadine	Antiviral activity against influenza virus A/Puerto Rico/8/34 H1N1 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza virus A/Puerto Rico/8/34 H1N1 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay	[PMID: 18954995]
MDCK	EC₅₀	3.3 μM Compound: 2	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells expressing M2 V27T/S31N mutant after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells expressing M2 V27T/S31N mutant after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	310 μM Compound: 2	Antiviral activity against Influenza A virus A/WS/33(H1N1) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus A/WS/33(H1N1) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	33.2 μM Compound: RMN	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	4 μg/mL Compound: Rimantadine	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	4 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	4 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	4.3 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	EC₅₀	4.6 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	40 μg/mL Compound: Rimantadin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	40 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	43.5 μM Compound: Rimantadine	Antiviral activity against 100 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N2) infected in dog MDCK cells assessed as virus-induced cytopathic effect after 48 hrs Antiviral activity against 100 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N2) infected in dog MDCK cells assessed as virus-induced cytopathic effect after 48 hrs	[PMID: 23489622]
MDCK	EC₅₀	44 μM Compound: Rimantadine	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	EC₅₀	45 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	45 μM Compound: RMN	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	5 μg/mL Compound: 5b	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as virus yield after 48 hrs end-point dilution method Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as virus yield after 48 hrs end-point dilution method	[PMID: 20006516]
MDCK	EC₅₀	5.1 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25899336]
MDCK	EC₅₀	5.3 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	5.45 μM Compound: Rimantadine	Antiviral activity against 1 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N2) infected in dog MDCK cells assessed as virus-induced cytopathic effect after 48 hrs Antiviral activity against 1 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N2) infected in dog MDCK cells assessed as virus-induced cytopathic effect after 48 hrs	[PMID: 23489622]
MDCK	EC₅₀	53 μg/mL Compound: Rimantadin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	58 μg/mL Compound: Rimantadin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	6.4 μM Compound: rimantadine	Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	62 μM Compound: Rimantadine	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect	[PMID: 27112451]
MDCK	EC₅₀	63 μM Compound: rimantadine	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	66.7 μM Compound: Rimantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25801933]
MDCK	EC₅₀	68 μg/mL Compound: Rimantadin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	7 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	7.6 μM Compound: rimantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25899336]
MDCK	ED₅₀	56.9 μM Compound: Rimantadine	Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method	[PMID: 23099095]
MDCK	IC₅₀	11 μM Compound: Rimantadine	Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) PA endonuclease infected in MDCK cells assessed as reduction in virus titer treated with cells for 1 hr prior to viral infection for 1 hr followed by compound washout and subsequent compound addit Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) PA endonuclease infected in MDCK cells assessed as reduction in virus titer treated with cells for 1 hr prior to viral infection for 1 hr followed by compound washout and subsequent compound addit	[PMID: 30390440]
MDCK	IC₅₀	44 μM Compound: Rimantadine	Antiviral activity against Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in chicken erythrocytes incubated for 1 hr with supernatants from 1 hr compound pre-treated MDCK cells infected with Influenza A virus (A/California/07/2009(H1N1)) pdm0 Antiviral activity against Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in chicken erythrocytes incubated for 1 hr with supernatants from 1 hr compound pre-treated MDCK cells infected with Influenza A virus (A/California/07/2009(H1N1)) pdm0	[PMID: 27591012]

In Vitro

Rimantadine (0-10 μg/mL, 72 h) inhibits the HAV subgenomic replicon and HAV replication in Huh7 and IHH cells infected with HAV HA11-1299 genotype IIIA^[1].
Rimantadine (0-10 μg/mL, 48 h) significantly inhibits HAV HM175 genotype IB subgenomic replicon replication dose-dependently in HuhT7 cells^[1].
Rimantadine (10 μg/mL, 1 h) significantly inhibits HAV HA11-1299 genotype IIA replication at the post-entry stage in Huh7 cells^[1].
Rimantadine (10 μg/mL, 48 h) enhances the expression of LC3, increases the number of lysosomes, and stimulates the fusion of lysosomes and autophagosomes in Huh7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Autophagy Assay^[1]

Cell Line:

HAV-infected Huh7 cell
Concentration:

0-10 μg/mL
Incubation Time:

72 h
Result:

Induced autophagy.

RT-PCR^[1]

Cell Line:

HAV-infected Huh7 cell
Concentration:

10 μg/mL
Incubation Time:

1 h
Result:

Significantly inhibited HAV replication both at full-time and at post-entry stages by 60% and 70% respectively.

Western Blot Analysis^[1]

Cell Line:

HAV-infected Huh7 cell
Concentration:

10 μg/mL
Incubation Time:

72 h
Result:

Upregulated the expression of LC3A and LC3B.
Inhibited the expression and phosphorylation of mTOR in HAV-infected Huh7 cells.

In Vivo

Rimantadine (5-20 mg/kg/day, p.o., twice daily for 5 d) prolongs survival of ICR mice infected with influenza A (H3N2) virus in combination with Oseltamivir (HY-13317)^[2].
Rimantadine (5-10 mg/kg/day, p.o., twice daily for 5 d) reduces the lung viral titers of ICR mice infected with influenza A (H3N2) virus in combination with Oseltamivir^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male white ICR mice infected with influenza A (H3N2) virus^[2]
Dosage:

5, 10, 20, 40 or 80 mg/kg/day
Administration:

Intraperitoneal injection (i.p.) twice daily for 5 d
Result:

Fully protected infected animals with 80 mg/kg/day incombination with 10 mg/kg/day Oseltamivir.
Decreased the infectious virus content.

Related Protocols :

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

CAS No. 13392-28-4
Appearance Liquid (Density: 1.033±0.06 g/cm³)
Masse moléculaire 179.30
Formule C₁₂H₂₁N
Color Colorless to light yellow
SMILES

CC(C1(C[C@H](C2)C3)C[C@H]3C[C@H]2C1)N
Synonyms

1-Rimantadine
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2026 Jun 10.

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (139.43 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.5772 mL

27.8862 mL

55.7724 mL

5 mM

1.1154 mL

5.5772 mL

11.1545 mL

10 mM

0.5577 mL

2.7886 mL

5.5772 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (13.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (13.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (13.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Sasaki-Tanaka R, et al., Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy. J Virol. 2022 Sep 28;96(18):e0064622. [Content Brief]

[2]. Simeonova L, et al., Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice. Antiviral Res. 2012 Aug;95(2):172-81. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.5772 mL	27.8862 mL	55.7724 mL	139.4311 mL
	5 mM	1.1154 mL	5.5772 mL	11.1545 mL	27.8862 mL
	10 mM	0.5577 mL	2.7886 mL	5.5772 mL	13.9431 mL
	15 mM	0.3718 mL	1.8591 mL	3.7182 mL	9.2954 mL
	20 mM	0.2789 mL	1.3943 mL	2.7886 mL	6.9716 mL
	25 mM	0.2231 mL	1.1154 mL	2.2309 mL	5.5772 mL
	30 mM	0.1859 mL	0.9295 mL	1.8591 mL	4.6477 mL
	40 mM	0.1394 mL	0.6972 mL	1.3943 mL	3.4858 mL
	50 mM	0.1115 mL	0.5577 mL	1.1154 mL	2.7886 mL
	60 mM	0.0930 mL	0.4648 mL	0.9295 mL	2.3239 mL
	80 mM	0.0697 mL	0.3486 mL	0.6972 mL	1.7429 mL
	100 mM	0.0558 mL	0.2789 mL	0.5577 mL	1.3943 mL

Bioz

Keywords

Rimantadine

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Rimantadine

Publications Citing Use of MedChemExpress (MCE) Rimantadine